Navigation Links
STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine
Date:1/14/2010

HORSHAM, Pa., Jan. 14 /PRNewswire/ -- Findings from an international, Phase 3 clinical study comparing the efficacy and safety of STELARA™ (ustekinumab) with etanercept (Enbrel®) in the treatment of moderate to severe plaque psoriasis appear today in The New England Journal of Medicine.  The results showed a significantly higher clinical response with both doses of STELARA than with etanercept over a 12-week period.  The first-of-its-kind head-to-head study comparing two biologic agents for plaque psoriasis also shows the efficacy of STELARA among patients in the study who failed to respond to etanercept.

Psoriasis is an inflammatory disorder characterized by raised, inflamed, red lesions, or plaques, which can cause physical pain.  It is estimated that approximately 7.5 million Americans and nearly 3 percent of the world's population are living with psoriasis, which can present in various forms, ranging from mild to severe and disabling. 

"This study provides important comparative efficacy information about the treatment of moderate to severe plaque psoriasis with two biologic agents," said professor Christopher Griffiths, MD, FRCP, University of Manchester, Manchester, UK, and lead trial investigator.  "We observed a substantial proportion of patients achieving high levels of skin clearance with ustekinumab, both through the study's primary endpoint at week 12 and following crossover from etanercept, including in those patients who showed a lack of response to etanercept during the study."

In the comparator study, 68 and 74 percent of patients receiving subcutaneous injections of STELARA (45 mg or 90 mg) at weeks 0 and 4 achieved at least a 75 percent reduction in psoriasis as measured by the Psoriasis
'/>"/>

SOURCE Centocor Ortho Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
2. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
3. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
6. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
7. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
8. Feeling Anxious or Distracted? New Research Shows a Cup of Tea Could Help
9. New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
10. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
11. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... , Oct. 1, 2014 Trovagene, Inc., ... announced today that Eli Diamond , MD, ... Center (MSK), presented clinical data from an ongoing ... monitoring platform for the determination of oncogene mutational ... biopsy.  The results were presented to both treating ...
(Date:10/1/2014)... MARCOS, Texas , Oct. 1, 2014 /PRNewswire/ ... it is scaling volume production of photoactive quantum ... power technologies . While offering numerous advantages for ... of producing large quantities of quantum dots with ... until now kept them from commercial utilization and ...
(Date:10/1/2014)... Oct. 1, 2014  CVS Health is thanking its ... role in changing the way health care is delivered ... the Company,s retail pharmacies, mail service pharmacies and specialty ... our company name to CVS Health to reflect our ... the innovations needed to shape the future of health," ...
Breaking Medicine Technology:Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 2Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 3Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 4Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 3CVS Health Thanking its Pharmacists during American Pharmacists Month for Helping People on Their Path to Better Health 2CVS Health Thanking its Pharmacists during American Pharmacists Month for Helping People on Their Path to Better Health 3
... 2012 i-Path Media LLC, a pharmaceutical marketing ... with their clients, received national certification as a ... Organization-New York Certification Committee, a regional certifying partner ... WBENC,s national standard of certification is ...
... Jan. 16, 2012  Palatin Technologies, Inc. (NYSE Amex: ... targeted, receptor-specific peptide therapeutics for the treatment of ... potential, today announced that Dr. Carl Spana, President ... Noble Financial Capital Markets, Eighth Annual Equity Conference.  ...
Cached Medicine Technology:Palatin Technologies to Present at BOCEMb, Noble Financial Capital Markets' Eighth Annual Equity Conference 2
(Date:10/1/2014)... Farmington Company today announced it has ... visual identity helping brokers, consultants and companies to ... create greater benefit communication synergies. They unveiled a ... customers to better leverage Farmington Company’s industry-tested experience ... the rebrand is the refreshed tagline: For the ...
(Date:10/1/2014)... Beverly Hills licensed Clinical Psychologist and nationally ... years of private practice in her Beverly Hills office ... greater joy and fulfillment in their relationships. Dr. Mojas ... suggestions for anyone who suspects they are in a ... or not, it’s not always easy to know when ...
(Date:10/1/2014)... NJ (PRWEB) October 01, 2014 Diet Doc ... their intentions to lose weight and their dieting attempts could ... fatty foods. Including hormone diet treatments into their ... allows patients to see fast and effective weight loss results, ... begin forming healthy habits to maintain their weight for the ...
(Date:10/1/2014)... Scientists at the University of Western Australia ... system proteins has the power to knock out mesothelioma ... the new study on their website. Click here ... the UWA School of Pathology and Laboratory Medicine administered ... mesothelioma with promising results. , “A timed triple ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Nordic ... benefit a very special cause. The campaign—“Buy One ... for Paws for Veterans, a nonprofit organization that ... also rescuing shelter dogs that would otherwise face ... featured products will support monthly donations of Nordic ...
Breaking Medicine News(10 mins):Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 4Health News:New Mesothelioma Study Says Mice Cured by Immuntherapy “Cocktail”, Reports Surviving Mesothelioma 2Health News:Nordic Naturals® Inspires Support for Paws for Veterans -- ‘Buy One Bottle. Help Two Heroes.’ Initiative Kicks Off October 1 2
... , ATLANTA and PHILADELPHIA, ... Technology, collaborating with pediatric cardiologists and surgeons at The ... virtual surgery that allows heart surgeons to view the ... cardiac magnetic resonance images of a patient,s specific anatomy, ...
... , , NIAGARA ... Pacific Corporation,s (Nasdaq: APFC ) wholly-owned in-space propulsion ... monopropellant engines, with a 30+ year history of successful space ... NASA,s Lunar Reconnaissance Orbiter (LRO) and Lunar Crater Observation and ...
... ... Technology for its Passport Assets Application Enabling Its Customers to Improve System Efficiency, Improve ... ... ASAP Systems today announced the release of its mobile RFID technology for their ...
... , , , ... device franchise, announced today the launch of eMed-Alert, a next-generation personal assistance ... in an emergency. With more than 11 million Americans age 65 ... their independence. , , "As baby ...
... , SOMERSET, N.J., Aug. 11 ... healthcare and administrative staffing services, will announce its third quarter financial results ... before the market opens. TeamStaff will host a conference call for ... Interested parties may participate in the call by dialing (877) ...
... PRINCETON, N.J., Aug. 11 Ranbaxy Pharmaceuticals Inc. (RPI), a ... that RLL has received final approval from the U.S. Food ... 25 mg (base), and 50 mg (base). The Office ... the Ranbaxy formulations to be bioequivalent and have the same ...
Cached Medicine News:Health News:MRI Simulation of Blood Flow Helps Plan Child's Heart Surgery 2Health News:MRI Simulation of Blood Flow Helps Plan Child's Heart Surgery 3Health News:MRI Simulation of Blood Flow Helps Plan Child's Heart Surgery 4Health News:MRI Simulation of Blood Flow Helps Plan Child's Heart Surgery 5Health News:AMPAC-ISP Engines Support Key NASA Lunar Missions 2Health News:ASAP Systems Introduces Mobile RFID Technology for its Passport Assets Application Enabling Increase Asset Management Flexibility 2Health News:ASAP Systems Introduces Mobile RFID Technology for its Passport Assets Application Enabling Increase Asset Management Flexibility 3Health News:World's First Emergency Medical Device Franchise Launches eMed-Alert 2Health News:World's First Emergency Medical Device Franchise Launches eMed-Alert 3Health News:TeamStaff, Inc. To Announce Third Quarter Results 2Health News:TeamStaff, Inc. To Announce Third Quarter Results 3Health News:Ranbaxy Receives Final Approval To Market Sumatriptan Succinate Tablets 2
... testing your blood glucose regularly, you want ... possible. Conventional spring-loaded lancet systems often penetrate ... cause painful dilation or tearing of skin ... a precise, linear action that provides greater ...
... Focus from Thermo Labsystems was designed specifically ... Advanced features such as the new fast ... on microvolumes help to define this as ... The new interchangeable handle plate offers a ...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,410-0) or contact custom...
... models cover the range from 2ul to 5000ul. ... Volume lock design prevents inadvertent volume change. ... Whole pipette is autoclavable at 121C(250F). ... polypropylene. Suitable for one-handed operation. Auto ...
Medicine Products: